Search results
Author(s):
Gurushankar Govindarajan
,
James R Sowers
,
Craig S Stump
Added:
3 years ago
There has been an increase in the prevalence of diabetes mellitus over the past 40 years, both in the US and worldwide. The worldwide prevalence of diabetes in 2000 was approximately 2.8% and is estimated to grow to 4.4% by 2030. This translates to a projected rise of diabetes from 171 million in 2000 to well over 350 million in 2030. The epidemic of diabetes will continue to rise as there is…
View more
Author(s):
Mohit Gupta
,
Borut Jug
,
Matthew J Budoff
Added:
3 years ago
Diabetes and Cardiovascular Disease
Diabetes has long been recognized as a major risk factor for cardiovascular disease and is widely regarded as a ‘coronary disease equivalent,’1,2 as diabetes and established coronary heart disease indicate a similar absolute risk for cardiovascular death in both men and women.3–5 Cardiovascular complications of diabetes have traditionally been regarded as…
View more
Author(s):
Allen B King
,
Gary S Wolfe
Added:
3 years ago
Excess cardiovascular disease (CVD) with diabetes has been recognized for some time. Among diabetic individuals, CVD accounts for >50% of all deaths, and stroke accounts for an additional 15%.1 Diabetic women are at particularly high risk of CVD; diabetes eliminates the well-described female advantage for coronary disease mortality.2 This is alarming since the prevalence of type 2 diabetes is…
View more
Author(s):
Samuel S Engel
Added:
5 months ago
EASD 2023 — In this short interview, Dr Samuel S Engel (Associate Vice President at Merck) discusses a study investigating the effectiveness and safety of efinopegdutide (MK-6024) in patients with nonalcoholic fatty liver disease and type 2 diabetes (NCT04944992).
The phase IIa study randomized 145 participants (efinopegdutide, n = 72; semaglutide, n = 73). The majority (55.2%) of participants…
View more
Author(s):
Domenic A Sica
Added:
3 years ago
Diabetes mellitus is rapidly increasing in its worldwide prevalence and is currently estimated to affect 7-8% of the US population.1 In 2005, 1.5 million new cases of diabetes were diagnosed in people aged 20 years or older in the US. In the not-so-distant past, type 2 diabetes mellitus was viewed as a seemingly benign condition, at least in the elderly, with little effect on life expectancy and…
View more
Author(s):
Harriette Van Spall
,
Neha Pagidipati
,
Christopher B Granger
Added:
1 year ago
ACC.23/WCC — Late-breaker host, Dr Harriette Van Spall (McMaster University,CA) is joined by Dr Neha J Pagidipati (Duke University Medical Center, US)and Dr Christopher B Granger (Duke University Medical Center, US)to discuss the results of the COORDINATE-Diabetes trial (NCT03936660).The COORDINATE-Diabetes trial is testing a multifaceted intervention to improve the care of people with type 2…
View more
Author(s):
Gemma Figtree
Added:
5 years ago
Gemma Figtree discusses the CANVAS trial - canagliflozin and heart failure in type 2 diabetes mellitus.
Filmed by Radcliffe Cardiology on-site at the American College of Cardiology congress 2018 in Orlando, USA.
View more
Author(s):
Erik M Kelly
,
Donald E Cutlip
Added:
3 years ago
Diabetes mellitus is one of the most common chronic diseases, affecting >30 million people in the US and 422 million worldwide.1,2 Alarmingly, both the incidence and prevalence of type 2 diabetes have doubled in the US since 1990.3 This is driven by an aging population, obesity, physical inactivity, and prolonged survival in those with diabetes, among other factors. It is estimated that…
View more
Author(s):
Cecilia Low Wang
Added:
2 years ago
Dr Cecilia Low Wang (Colorado Prevention Center, US) discusses the findings from the VOYAGER PAD - rivaroxaban in symptomatic PAD with and without comorbid diabetes study. The study assessed the efficacy and safety of rivaroxaban in patients with PAD with concomitant diabetes after lower extremity revascularization.
The study presented at ESC Congress 2021 showed that the efficacy of rivaroxaban…
View more
Author(s):
Hou Tee Lu
,
Rusli Bin Nordin
,
Aizai Azan Bin Abdul Rahim
Added:
3 years ago
Heart failure (HF) is a global public health problem, affecting an estimated 26 million people worldwide and resulting in more than 1 million hospitalizations annually in the US and Europe.1 This HF pandemic is also evident in Asia and other parts of the world.2–4 Although the outcomes for HF patients have improved with the discovery of multiple evidence-based drug and device therapies,…
View more